May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
A Novel Cell Adhesion Inhibitor, K-7174, Reduces Lymphocyte Infiltration and Increases Tear Production in Sjögren's Syndrome Model Mouse
Author Affiliations & Notes
  • K. Tsubota
    Department of Ophthalmology, Tokyo Dental College, Ichikawa, Japan
  • Y. Ohashi
    Department of Ophthalmology, Tokyo Dental College, Ichikawa, Japan
  • A. Higuchi
    Department of Ophthalmology, Tokyo Dental College, Ichikawa, Japan
  • H. Inoue
    Department of Ophthalmology, Tokyo Dental College, Ichikawa, Japan
  • T. Doi
    Tokyo New Drug Research Laboratories II, Kowa Co., Ltd, Tokyo, Japan
  • C. Mataki
    Department of Molecular Biology & Medicine, University of Tokyo, Tokyo, Japan
  • T. Kodama
    Department of Molecular Biology & Medicine, University of Tokyo, Tokyo, Japan
  • Y. Hayashi
    Department of Pathology, Tokushima University, Tokushima, Japan
  • I. Saito
    Department of Pathology, Tsurumi University, Yokohama, Japan
  • Footnotes
    Commercial Relationships  K. Tsubota, Kowa Co., Ltd. F; Y. Ohashi, None; A. Higuchi, None; H. Inoue, None; T. Doi, None; C. Mataki, None; T. Kodama, None; Y. Hayashi, None; I. Saito, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2511. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Tsubota, Y. Ohashi, A. Higuchi, H. Inoue, T. Doi, C. Mataki, T. Kodama, Y. Hayashi, I. Saito; A Novel Cell Adhesion Inhibitor, K-7174, Reduces Lymphocyte Infiltration and Increases Tear Production in Sjögren's Syndrome Model Mouse . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2511.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate the effect of a novel cell adhesion inhibitor, K-7174, for the improvement of dry eye in Sjögren’s model mouse. Methods: A total of 30 NFS/sld thymectomized mice, 4 weeks after birth, were treated by oral administration (N=15, vehicle, 10m/kg and 30mg/kg) or topical application (N=15, vehicle, 0.8mg/ml, and 2.4mg/ml) of K-7174 for 10 weeks. Tear secretion was measured by cotton thread and lymphocyte infiltration in the lacrimal glands were graded. Gene expression of lacrimal glands, with and without treatment, were assayed by gene-chip analysis (Affymetrix). Results: Tear secretion increased to 0.175 +/- 0.062 (10mg/kg) and 0.198 +/- 0.039 (30mg/kg) in oral administered groups compared to 0.092 +/- 0.030 mm/min/g (vehicle). Similar results were obtained in the topical treatment group. Lymphocyte infiltration grades decreased to 0.63 +/- 0.31 (10mg/kg) and 0.0 +/- 0.0 (30mg/kg) compared to 3.71 +/- 0.41 (vehicle). Similar results were obtained in topical administered groups (0.6+/-0.48 in 2.4mg/ml, 0.6 +/- 0.48 in 0.8mg/ml and 2.6+/- 0.9 in vehicle). Fractalkine, a newly discovered lymphocyte trafficking chemokine, was found to be suppressed dramatically in the lacrimal gland of treated mice among the 11 suppressed genes. Conclusion: Both systemic and topical application of K-7174 increases tear secretion and decreases lymphocyte infiltration of lacrimal glands in NFS/sld thymectomized mice. K-7174 could possibly be a new drug for the control of inflammation of Sjögren's syndrome and Fractalkine may one of the target molecules in this treatment mechanism.

Keywords: conjunctiva • cornea: epithelium • lacrimal gland 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×